title: Clinical trials in recurrent ovarian cancer.
abstract: The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?
authors.affiliation: ANZGOG, Australia-New Zealand. michael.friedlander@sesiahs.health.nsw.gov.au
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
authors.forename: Edward
authors.initials: E
authors.lastname: Trimble
authors.forename: Anna
authors.initials: A
authors.lastname: Tinker
authors.forename: David
authors.initials: D
authors.lastname: Alberts
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Avall-Lundqvist
authors.forename: Mark
authors.initials: M
authors.lastname: Brady
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.forename: Eric
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.forename: Philip
authors.initials: P
authors.lastname: Beale
authors.forename: Rudd
authors.initials: R
authors.lastname: Bekkers
authors.forename: Paula
authors.initials: P
authors.lastname: Calvert
authors.forename: Lawrence
authors.initials: L
authors.lastname: Copeland
authors.forename: Ros
authors.initials: R
authors.lastname: Glasspool
authors.forename: Antonio
authors.initials: A
authors.lastname: Gonzalez-Martin
authors.forename: Dionysis
authors.initials: D
authors.lastname: Katsaros
authors.forename: Jae Won
authors.initials: JW
authors.lastname: Kim
authors.forename: Brigitte
authors.initials: B
authors.lastname: Miller
authors.forename: Diane
authors.initials: D
authors.lastname: Provencher
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rubinstein
authors.forename: Mostafa
authors.initials: M
authors.lastname: Atri
authors.forename: Alain
authors.initials: A
authors.lastname: Zeimet
authors.forename: Monica
authors.initials: M
authors.lastname: Bacon
authors.forename: Henry
authors.initials: H
authors.lastname: Kitchener
authors.forename: Gavin C E
authors.initials: GC
authors.lastname: Stuart
mesh_terms: D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends; D032921:Consensus; D023381:Endpoint Determination / Q000379:methods; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000379:methods / Q000639:trends; D006801:Humans; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D012008:Recurrence